Cetuximab is a monoclonal antibody used to treat certain types of cancer, particularly colorectal cancer and head and neck cancer. It works by inhibiting the epidermal growth factor receptor (EGFR), which plays a crucial role in the growth and spread of cancer cells.
The cetuximab market is predicted to develop at a compound annual growth rate (CAGR) of x% from 2024 to 2034, when it is...
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Russian
Romaian